Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)
 
 • Company Description   
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Number of Employees: 191

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.28 Daily Weekly Monthly
20 Day Moving Average: 1,048,413 shares
Shares Outstanding: 207.69 (millions)
Market Capitalization: $265.85 (millions)
Beta: 2.43
52 Week High: $8.72
52 Week Low: $1.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.95% -14.48%
12 Week -37.26% -31.92%
Year To Date -65.50% -58.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20374 Seneca Meadows Parkway
-
Germantown,MD 20876
USA
ph: 301-556-9900
fax: -
investors@precigen.com http://www.precigen.com
 
 • General Corporate Information   
Officers
Helen Sabzevari - Chief Executive Officer
Randal J. Kirk - Chairman
Harry Thomasian Jr. - Chief Financial Officer
Cesar L. Alvarez - Director
Steven Frank - Director

Peer Information
Precigen, Inc. (CORR.)
Precigen, Inc. (RSPI)
Precigen, Inc. (CGXP)
Precigen, Inc. (BGEN)
Precigen, Inc. (GTBP)
Precigen, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74017N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 207.69
Most Recent Split Date: (:1)
Beta: 2.43
Market Capitalization: $265.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.60
Price/Cash Flow: -
Price / Sales: 2.39
EPS Growth
vs. Year Ago Period: 9.09%
vs. Previous Quarter: 23.08%
Sales Growth
vs. Year Ago Period: 30.64%
vs. Previous Quarter: 32.20%
ROE
03/31/22 - -79.87
12/31/21 - -67.60
09/30/21 - -68.90
ROA
03/31/22 - -25.54
12/31/21 - -25.03
09/30/21 - -24.44
Current Ratio
03/31/22 - 6.05
12/31/21 - 4.52
09/30/21 - 5.28
Quick Ratio
03/31/22 - 5.55
12/31/21 - 4.14
09/30/21 - 4.94
Operating Margin
03/31/22 - -84.55
12/31/21 - -93.16
09/30/21 - -92.65
Net Margin
03/31/22 - -84.48
12/31/21 - -88.73
09/30/21 - -109.91
Pre-Tax Margin
03/31/22 - -84.70
12/31/21 - -93.31
09/30/21 - -112.68
Book Value
03/31/22 - 0.36
12/31/21 - 0.52
09/30/21 - 0.64
Inventory Turnover
03/31/22 - 5.28
12/31/21 - 5.16
09/30/21 - 5.28
Debt-to-Equity
03/31/22 - 2.72
12/31/21 - 1.70
09/30/21 - 1.37
Debt-to-Capital
03/31/22 - 73.14
12/31/21 - 63.00
09/30/21 - 57.81
 

Powered by Zacks Investment Research ©